Table 1.
Clinicopathologic characteristics
| Characteristic | No. (%) |
|---|---|
| Age (yr) | |
| Median (range) | 65 (23–82) |
| Sex | |
| Male | 191 (47.4) |
| Female | 212 (52.6) |
| Smoking statusa | |
| Never | 242 (60.0) |
| Ex-smoker | 89 (22.1) |
| Current | 72 (17.9) |
| Differentiationb | |
| Well differentiated | 34 (8.4) |
| Moderately differentiated | 315 (78.2) |
| Poorly differentiated | 54 (13.4) |
| Genetic statusc | |
| EGFR mutant | 192 (69.1) |
| ALK mutant | 20 (7.2) |
| KRAS mutant | 16 (5.8) |
| EGFR(–)/ALK(–)/KRAS(–) | 50 (18.0) |
| Tumor size (cm) | |
| Mean (range) | 31.7 (0.8–16.0) |
| Pleural invasion | |
| Absent | 235 (58.3) |
| Present | 168 (41.7) |
| Venous invasion | |
| Absent | 302 (74.9) |
| Present | 101 (25.1) |
| Lymphatic invasion | |
| Absent | 213 (52.9) |
| Present | 190 (47.1) |
| Perineural invasion | |
| Absent | 380 (94.3) |
| Present | 23 (5.7) |
| Pathologic stage | |
| IA | 127 (31.5) |
| IB | 107 (26.6) |
| IIA | 64 (15.9) |
| IIB | 19 (4.7) |
| IIIA | 77 (19.1) |
| IIIB | 9 (2.2) |
| HLA class I IHC (%) | |
| < 25 | 249 (61.8) |
| 25–74 | 120 (29.8) |
| ≥ 75 | 34 (8.4) |
| PD-L1 IHC (%) | |
| < 1 | 338 (83.9) |
| 1–49 | 42 (10.4) |
| ≥ 50 | 23 (5.7) |
| Total | 403 (100) |
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; HLA, human leukocyte antigen; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1.
Smoking status was defined as follows: never smoker (< 100 cigarettes per lifetime); ex-smoker (≥ 100 cigarettes per lifetime and quit > 1 year prior to the diagnosis); current smoker (≥ 100 cigarettes per lifetime and smoked at the time of lung cancer diagnosis or quit ≤ 1 year prior to the diagnosis);
Differentiation was defined as follows: well differentiated (lepidic predominant); moderately differentiated (acinar or papillary predominant); poorly differentiated (micropapillary or solid predominant);
Genetic status was evaluable for 278 patients.